Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Reunion Neuroscience’s psychedelic has reduced the symptoms of postpartum depression in a phase 2 study, setting up the ...

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Under the agreement, Skyhawk will use its RNA splicing platform, dubbed ...

Jayanta Bhattacharya, M.D., Ph.D., director of the National Institutes of Health (NIH), has called on the agency’s scientific ...

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Philips is planning to invest at least $150 million in new funding for its U.S. production base, including through the ...

Omeros’ efforts to get its transplant drug to market have already suffered one FDA rejection. | Omeros’ efforts to get its ...

Experienced business developer Derek Hicks has been handed the reins of Rezo Therapeutics, his first time at the helm of a ...

Evotec’s sweeping reorganization has claimed roughly 600 jobs since last March, 200 more than were originally planned under a ...

Generation Bio is shedding 90% of its workforce after the biotech acknowledged it’s unlikely to find the cash to take its ...

Prelude Therapeutics’ lead asset won’t be making it to the second act. | Prelude Therapeutics’ lead asset won’t be making it ...

After the Department of Health and Human Services canceled about $500 million in funding for mR | After HHS abruptly canceled ...